Ted Love is the founder of Global Blood Therapeutics. Latest round: Series B. Backed by Wellington Management Company LLP, RA Capital, Deerfield Management.
Ted Love was the CEO of Global Blood Therapeutics (GBT), a biopharmaceutical company focused on developing therapies for severe blood disorders. Under his leadership, GBT completed a $48 million Series B financing round to advance its lead drug candidate, GBT440, for sickle cell disease.
Full founder directory · Investor directory · Company funding database · Fundraising library